Last reviewed · How we verify
Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology (NintNivo)
Determination of a safe dose for nintedanib+nivolumab combination therapy and the generation of exploratory efficacy data in pretreated patients with advanced or metastatic NSCLC of adenocarcinoma histology.
Details
| Lead sponsor | AIO-Studien-gGmbH |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | COMPLETED |
| Enrolment | 56 |
| Start date | Fri May 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Sep 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Adenocarcinoma of the Lung
Interventions
- nintedanib-nivolumab combination therapy
Countries
Germany